VERACYTE, INC. (VCYT) research
VERACYTE, INC.- Sector
- Biotechnology
- Last price
- $45.81
- As of
VERACYTE, INC. (VCYT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for VCYT. Method and limitations.
Share the VCYT intelligence card
See the full VCYT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VCYT on one page. Preview it with sample data, then open it live with a free account.
Preview the VCYT dossierActive signals for VCYT
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +52% to VCYT (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 66% of VCYT (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 51% of VCYT (2026Q2)
- highINSTITUTIONAL_SURGE
D. E. Shaw & Co., Inc. added +880% to VCYT (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 28.2%, EPS $0.31 vs $0.2419 estimate
FREE, NO ACCOUNT
Every signal on VCYT, as it fires
You are seeing 5 of 15 signals recorded on VCYT since 2026-05-26.
The five above landed across 2 days. The other 10 were recorded on 2 other days. 9 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VCYT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 92337F107 · 2026Q2 | $43.3M | 0.05% | , |
| D. E. Shaw & Co., Inc.CUSIP 92337F107 · 2026Q2 | $24.3M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 92337F107 · 2026Q2 | $4.2M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 92337F107 · 2026Q2 | $3.4M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VCYT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VCYT against its peers
VCYT's operating margin of 11.2% ranks in the 91st percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | VCYT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 517M USD | 62.4M USD | 75 | 17 |
| Gross margin | 70.1% | n/a | n/a | 1 |
| Operating margin | 11.2% | -153.1% | 91 | 15 |
| Net margin | 12.8% | -148.4% | 84 | 15 |
| Return on equity | 5.1% | -29.8% | 85 | 23 |
| P / E | 55.9x | n/a | n/a | 1 |
Peers (23): IDYA, XENE, CPRX, RLAY, CELC, LEGN, ACAD, TLX, ARQT, GRTX, ELVN, DNLI, TNGX, VKTX, RCUS, EWTX, DYN, ZLAB, NAMS, DNTH, PGEN, MBX, IOVA. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (VCYT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more VCYT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to VCYTand get the insider, 13F, options, and confluence read in one view.